DexCom Reports Officer Changes and Compensation Details
Ticker: DXCM · Form: 8-K · Filed: Oct 27, 2025 · CIK: 1093557
| Field | Detail |
|---|---|
| Company | Dexcom INC (DXCM) |
| Form Type | 8-K |
| Filed Date | Oct 27, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $500,000, $345,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: officer-changes, director-changes, compensation, regulation-fd
Related Tickers: DXCM
TL;DR
DexCom filed an 8-K on 10/27 for 10/24 events: officer/director changes & comp. Watch for impacts.
AI Summary
DexCom, Inc. filed an 8-K on October 27, 2025, reporting events on October 24, 2025. The filing pertains to the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes Regulation FD disclosures and financial statements/exhibits.
Why It Matters
This filing indicates potential shifts in leadership or executive compensation at DexCom, which could impact the company's strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in key officers or directors, especially if accompanied by new compensation structures, can signal strategic shifts or internal dynamics that may affect the company's future performance.
Key Players & Entities
- DEXCOM INC (company) — Registrant
- October 24, 2025 (date) — Earliest Event Reported
- October 27, 2025 (date) — Date of Report
FAQ
What specific officer or director positions were affected by the events reported on October 24, 2025?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers' but does not specify names or exact roles within this 8-K header.
Are there any new compensatory arrangements for officers detailed in this filing?
Yes, the filing explicitly lists 'Compensatory Arrangements of Certain Officers' as an item of disclosure, suggesting new or updated compensation plans are being reported.
What is the significance of the Regulation FD Disclosure mentioned?
Regulation FD (Fair Disclosure) ensures that material non-public information is disclosed to all investors simultaneously, so this section likely contains information that DexCom is making public to comply with this rule.
Does this filing include any financial statements?
Yes, the filing explicitly states 'Financial Statements and Exhibits' as an item of disclosure, indicating that financial information is being provided.
What is the primary business of DexCom, Inc. based on the SIC code?
DexCom, Inc. is classified under SIC code 3841, which corresponds to 'Surgical & Medical Instruments & Apparatus'.
Filing Stats: 950 words · 4 min read · ~3 pages · Grade level 9.9 · Accepted 2025-10-27 16:15:56
Key Financial Figures
- $0.001 — ange on Which Registered Common Stock, $0.001 Par Value Per Share DXCM Nasdaq Global
- $500,000 — ock units ("RSUs") with a fair value of $500,000, vesting annually over the three years
- $345,000 — of a grant of RSUs with a fair value of $345,000 for his service on the Board and commit
Filing Documents
- dxcm-20251024.htm (8-K) — 30KB
- dxcm20251024-exhibit991.htm (EX-99.1) — 7KB
- dxcm-20251024_g1.jpg (GRAPHIC) — 108KB
- 0001093557-25-000264.txt ( ) — 403KB
- dxcm-20251024.xsd (EX-101.SCH) — 2KB
- dxcm-20251024_lab.xml (EX-101.LAB) — 21KB
- dxcm-20251024_pre.xml (EX-101.PRE) — 12KB
- dxcm-20251024_htm.xml (XML) — 3KB
01. REGULATION FD DISCLOSURE
ITEM 7.01. REGULATION FD DISCLOSURE. On October 27, 2025, Dexcom announced the appointment of Dr. Ashley to the Board in a press release furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.
01. FINANCIAL STATEMENTS AND EXHIBITS
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits. Number Description 99.1 Press release dated October 27, 2025 104 Cover Page Interactive Data File (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DEXCOM, INC. By: /s/ JEREME M. SYLVAIN Jereme M. Sylvain Executive Vice President, Chief Financial Officer Date: October 27, 2025